Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Sanofi logo at the company's headquarters during the annual results news conference in Paris (Reuters) -Sanofi won ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License ...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly ...

July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) has approved their Dupixent injection for the treatment of adult patients ...

Dupixent is a prescription injection that treats several conditions, including eczema, asthma, COPD, and rhinosinusitis. A copay card may assist you with Dupixent’s cost. Dupixent is a brand-name ...

Targeted treatments have emerged as a safer and more effective option for eczema patients, but high costs remain a barrier.

Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder. It’s the ...

Dupixent also met all secondary endpoints in both trials, including demonstrating a significant reduction in the need for systemic corticosteroids or surgery, and improvements in smell and chronic ...

First biologic approved in the European Union for adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) Dupixent now approved in the EU for three type 2 inflammatory diseases: severe ...

Adverse events more commonly observed with Dupixent and TCS included conjunctivitis, nasopharyngitis and injection site reactions, which is consistent with the previously documented safety profile of ...

May 20 (Reuters) - Sanofi (SASY.PA), opens new tab won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug ...